The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque psoriasis.
Participants will take one tablet daily of either zasocitinib or a matching placebo, along with one capsule daily of either over-encapsulated deucravacitinib or a matching placebo, for a duration of 16 weeks.
Participants will be in the study for up to 25 weeks, which includes screening period of up to 35 days, a 16-week treatment period, and a 4-week safety follow-up period.
Protocol Amendment History
6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-05-08; most recent amendment 2026-04-27.
Status change: Active, Not Recruiting → Completed2026-04-27
Status change: Recruiting → Active, Not Recruiting2025-12-11
Status change: Not Yet Recruiting → Recruiting2025-07-22